Thomas Foster, MD
Neurology · Mobile, ALNPI 1992962856
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,795 of the $51,203 with a category attached, or 85.5%. AbbVie accounts for 94.0% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2020 at $23,354 and has fallen 97.8% since, to $515 in 2025.
Across 442 payments — averaging $115.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$48K
- Biogen$345
- Novartis$317
- Teva Pharmaceuticals USA, Inc.$278
- Amgen$253
- UCB, Inc.$215
- plus $2K from 30 others
What the payments were for
- Consulting fees$1500%
- Speaking & faculty fees$43,79586%
- Travel & lodging$1,5413%
- Food & beverage$5,69911%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 245 | $48,149 |
| Biogen | 18 | $345 |
| Novartis | 25 | $317 |
| Teva Pharmaceuticals USA, Inc. | 16 | $278 |
| Amgen(2 entities) | 15 | $253 |
| UCB, Inc. | 12 | $215 |
| Impel Pharmaceuticals Inc. | 16 | $207 |
| AstraZeneca | 8 | $139 |
| Arbor Pharmaceuticals, Inc. | 11 | $127 |
| EMD Serono, Inc. | 7 | $107 |
| Lundbeck LLC | 4 | $101 |
| Lilly USA, LLC | 5 | $77 |
| Sunovion Pharmaceuticals Inc. | 6 | $77 |
| Acadia Pharmaceuticals Inc | 6 | $73 |
| Neurocrine Biosciences, Inc. | 4 | $69 |
| Ipsen Biopharmaceuticals, Inc | 4 | $61 |
| Amneal Pharmaceuticals LLC | 5 | $57 |
| Bristol Myers Squibb | 4 | $53 |
| Genentech USA, Inc. | 4 | $52 |
| Medtronic | 3 | $42 |
| Pfizer | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| MDD US Operations, LLC | 1 | $37 |
| Avion Pharmaceuticals | 2 | $35 |
| Sanofi | 2 | $35 |
| Johnson & Johnson | 2 | $31 |
| Adamas Pharmaceuticals, Inc. | 2 | $27 |
| Upsher-smith Laboratories LLC | 2 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Merz Pharmaceuticals, LLC | 1 | $22 |
| Eisai Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Averitas Pharma Inc. | 1 | $14 |
| Catalyst Pharmaceuticals, Inc. | 1 | $14 |
| Vertical Pharmaceuticals, LLC | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,203 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 46 | $282,827 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $238,331 |
| UbrelvyUbrogepant | 67 | $98,252 |
| BotoxOnabotulinumtoxina | 60 | $71,863 |
| Nurtec OdtRimegepant Sulfate | 44 | $58,563 |
| QuliptaAtogepant | 42 | $56,571 |
| Emgality PenGalcanezumab-Gnlm | 33 | $39,428 |
| Aimovig AutoinjectorErenumab-Aooe | 25 | $29,555 |
| RytaryCarbidopa/Levodopa | 15 | $20,791 |
| EliquisApixaban | 17 | $13,951 |
| FycompaPerampanel | 12 | $13,941 |
| Gabapentin | 551 | $9,831 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,577 |
| Memantine Hcl | 397 | $9,332 |
| Pregabalin | 205 | $8,899 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $73 | $282,82746 claims |
| AbbVieUbrelvy, Botox, Qulipta | $48,149 | $226,687169 claims |
| PfizerNurtec Odt, Eliquis | $40 | $72,51461 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $57 | $25,20373 claims |
| Eisai Inc.Fycompa | $17 | $13,94112 claims |
| Upsher-smith Laboratories LLCTopiramate | $25 | $2,161180 claims |
| Lilly USA, LLCOlanzapine | $77 | $2,15278 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 255 neurology providers in Alabama.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Charles MarkleMobile$212K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
- Juan OchoaMobile$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.